Sarepta Therapeutics is down 70.4% since the beginning of the year, and at $36.69 per share, it is trading 77.6% below its 52-week high of $163.85 from June 2024.

Louise Rodino-Klapac; Executive Vice President, Chief Scientific Officer, Head of R and D; Sarepta Therapeutics Inc Ian Estepan; Chief Financial Officer, Executive Vice President; Sarepta ...

Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show ...

About EXONDYS 51 EXONDYS 51 uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin pre-mRNA, resulting in ...

YOU are absolutely right! The name ‘Shankar’ and chapli kebab is an anomaly of the highest order. Bear with me. In this unfortunate atmosphere of war, where even the usually saner elements ...

Sarepta posted Q1 2025 revenue of $744.86 million, beating the $683.36 million estimate. Full-year revenue guidance cut to $2.3 billion–$2.6 billion from prior $2.9 billion–$3.1 billion range ...

Sarepta Therapeutics, Inc. SRPT posted a loss for the first quarter on Tuesday. Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of ...

On Thursday, Evercore ISI downgraded Sarepta Therapeutics (NASDAQ:SRPT) stock from "Outperform" to "In Line," significantly reducing the price target to $50 from the previous $123. The stock ...

Louise Rodino-Klapac; Executive Vice President, Chief Scientific Officer, Head of R and D; Sarepta Therapeutics Inc Ian Estepan; Chief Financial Officer, Executive Vice President; Sarepta Therapeutics ...

The last time I wrote about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) it was in an article entitled "Sarepta Therapeutics: BLA Filing of SRP-9003 For LGMD Is The Next Step." In this article ...

Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market. The stock tumbled 21%, to $36.75, in after-hours ...

We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other ...